Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma | Zendy

Antje Wick | Zendy; Jörg Felsberg | Zendy; Joachim P. Steinbach | Zendy; Ulrich Herrlinger | Zendy; Michael Platten | Zendy; Britta Blaschke | Zendy; Richard Meyermann | Zendy; Guido Reifenberger | Zendy; Michael Weller | Zendy; Wolfgang Wick | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma

Author(s) -

Antje Wick,

Jörg Felsberg,

Joachim P. Steinbach,

Ulrich Herrlinger,

Michael Platten,

Britta Blaschke,

Richard Meyermann,

Guido Reifenberger,

Michael Weller,

Wolfgang Wick

Publication year - 2007

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2007.10.7722

Subject(s) - temozolomide , medicine , regimen , tolerability , oncology , common terminology criteria for adverse events , glioma , progression free survival , chemotherapy regimen , lomustine , dacarbazine , chemotherapy , adverse effect , surgery , vincristine , cyclophosphamide , cancer research

Evaluation of toxicity and efficacy of an alternating weekly regimen of temozolomide administered 1 week on and 1 week off in patients with recurrent glioma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research